Olema Pharmaceuticals Stock Surges on Major Clinical Partnerships

Shares of clinical-stage biopharmaceutical company Olema Pharmaceuticals experienced a dramatic rally in September, climbing nearly 50% in a single month. This significant upward movement was fueled by a major development: the company secured a second strategic collaboration with pharmaceutical giant Pfizer, further validating its lead drug candidate.

The recent surge was triggered by the announcement of a new clinical co-development agreement. Olema and Pfizer will jointly investigate a combination therapy pairing Olema’s promising oral drug, palazestrant (OP-1250), with Pfizer’s experimental CDK4 inhibitor, atirmociclib (PF-07220060). The companies plan to initiate a Phase Ib/II clinical trial involving approximately 35 patients before the end of the year. This marks the second significant partnership between the two firms, signaling strong confidence in the asset’s potential.

Beyond the Pfizer collaboration, Olema is also advancing a separate clinical program with another industry leader, Novartis. This partnership is evaluating palazestrant in combination with Novartis’ FDA-approved medicine, Kisqali (ribociclib). A crucial Phase III trial for this combination, designated OPERA-02, is scheduled to commence within the current quarter.

Should investors sell immediately? Or is it worth buying Olema Pharmaceuticals?

Concurrently, the company is progressing its pivotal OPERA-01 study, which is testing palazestrant as a standalone monotherapy for advanced breast cancer. Initial topline results from this late-stage trial are anticipated in the second half of 2026.

This robust and promising clinical pipeline has captured the attention of market analysts. The consensus price target for Olema Pharmaceuticals sits in the $24 to $25 range, implying a potential upside of almost 200% from recent trading levels. It is important for investors to note that, as a pre-commercial company, Olema currently reports negative earnings and cash flow. Its valuation is therefore entirely dependent on the future success of its drug candidates.

The performance of Olema’s stock serves as a powerful example of how clinical developments and high-profile alliances can create substantial market momentum, even for companies in the development phase. Whether this rally continues will be directly tied to the readouts from these ongoing and upcoming clinical studies.